=== SYSTEM ===
You are an expert in space medicine, bioinformatics, and multi-omics data analysis. You are answering questions about spaceflight biomedical data from the SpaceOmicsBench benchmark, which includes data from the Inspiration4 (I4) 3-day mission and the NASA Twins Study (340-day ISS mission).

When answering:
1. Be specific and cite relevant statistics when available from the provided context
2. Distinguish between what the data shows versus your interpretation
3. Express uncertainty appropriately, especially given the extremely small sample sizes (N=4 for I4, N=1 for Twins)
4. Consider multi-omics integration and cross-mission comparisons where relevant
5. Do not fabricate statistics, gene names, or citations not present in the provided context

=== PROMPT ===
## Data Context

# Clinical Biomarker Data

## Dataset
- **Source**: Inspiration4 mission, 4 civilian crew (C001-C004)
- **Samples**: 28 total (4 crew × 7 timepoints)
- **Phase distribution**: pre_flight=12, post_flight=4, recovery=12

## CBC (Complete Blood Count) — 20 features
Absolute counts: basophils, eosinophils, lymphocytes, monocytes, neutrophils
Percentages: basophils, eosinophils, lymphocytes, monocytes, neutrophils
Red cell indices: hematocrit, hemoglobin, MCH, MCHC, MCV, RBC count, RDW
Platelets: platelet count, MPV
White cells: WBC count

## CMP (Comprehensive Metabolic Panel)
Standard metabolic markers measured at same timepoints as CBC.

## Cytokines/Immune Markers — 71 features
EVE (extravehicular exposure) cytokine panel including inflammatory markers, growth factors, and chemokines. Measured in serum at all 7 timepoints.

## Benchmark Tasks
- **A1**: Flight phase classification from CBC + CMP features (3-class: pre/post/recovery)
  - Metric: macro_f1, LOCO evaluation (4-fold)
  - Best baseline: LogReg = 0.546
- **A2**: Flight phase classification from immune/cytokine markers (3-class)
  - Metric: macro_f1, LOCO evaluation (4-fold)
  - Best baseline: LogReg = 0.493

## Key Observations
- Post-flight class has only 4 samples (one per crew at R+1), creating severe imbalance
- CBC features show acute changes at R+1 including shifts in neutrophil/lymphocyte ratios
- LogReg outperforms RF and MLP, likely due to small N favoring simpler models
- LOCO evaluation is stringent: each fold tests on an entirely unseen crew member

---

# SpaceOmicsBench — Mission and Benchmark Overview

## Benchmark Summary
SpaceOmicsBench is a multi-omics AI benchmark for spaceflight biomedical data, featuring 21 ML tasks across 9 modalities from three human spaceflight studies.

## Missions

### Inspiration4 (I4)
- **Type**: SpaceX commercial crew mission, first all-civilian orbital spaceflight
- **Date**: September 15-18, 2021
- **Duration**: ~3 days in low Earth orbit (LEO, ~585 km altitude)
- **Crew**: 4 civilians (C001-C004), no prior spaceflight experience
- **Sample collection**: 7 timepoints — L-92, L-44, L-3 (pre-flight), R+1 (post-flight), R+45, R+82, R+194 (recovery)
- **Modalities collected**: CBC, CMP, cytokines, cfRNA, proteomics (plasma + EVP), metabolomics, spatial transcriptomics (skin), microbiome (10 body sites + ISS environmental)
- **Data source**: NASA OSDR (OSD-569 to OSD-687)

### JAXA Cell-Free Epigenome (CFE) Study
- **Type**: ISS long-duration mission study
- **Duration**: >120 days aboard ISS
- **Subjects**: 6 astronauts
- **Focus**: Cell-free RNA epigenome analysis
- **Data source**: NASA OSDR (OSD-530)

### NASA Twins Study
- **Type**: Year-long ISS mission with identical twin control
- **Date**: March 2015 - March 2016
- **Duration**: 340 days aboard ISS
- **Subjects**: Scott Kelly (space, N=1) vs Mark Kelly (ground control, N=1)
- **Blood cell analysis**: Single-cell RNA-seq of CD4, CD8, CD19, PBMC, LD (lymphocyte-depleted)
- **Contrasts analyzed**: 21 different coefficients (In-flight vs Pre-flight, Post-flight vs Pre-flight, etc.)
- **Total DEG entries**: 115,493 across all cell types and contrasts (19,446 unique genes)

## Benchmark Structure

| Property | Value |
|----------|-------|
| Total tasks | 21 (19 main + 2 supplementary) |
| Categories | A (Clinical), B (cfRNA), C (Proteomics), D (Metabolomics), E (Spatial), F (Microbiome), G (Multi-modal), H (Cross-tissue), I (Cross-mission) |
| Difficulty tiers | Calibration (1), Standard (5), Advanced (8), Frontier (7) |
| Evaluation strategies | LOCO (leave-one-crew-out), LOTO (leave-one-timepoint-out), Feature 80/20 (stratified) |
| ML baselines | Random, Majority, LogReg, RF, MLP |

## Flight Phases
- **pre_flight**: Samples collected before launch (L-92, L-44, L-3)
- **in_flight**: During spaceflight (I4 only ~3 days; Twins ~340 days)
- **post_flight**: Immediately after return (R+1)
- **recovery**: Extended post-flight period (R+45, R+82, R+194)

## Key Challenges
- Extremely small sample sizes: N=4 crew (I4), N=1 treatment (Twins)
- High dimensionality: 2,845 proteins, 26,845 genes, 433 metabolites
- Class imbalance: some tasks have <0.2% positive rate
- Cross-mission comparisons: 3-day vs 340-day missions with different measurement platforms

---

# Ground Truth Key Facts

## Mission Facts
- I4: 4 civilian crew, 3 days LEO (~585 km), September 2021, SpaceX Dragon
- NASA Twins: 340 days ISS, Scott Kelly vs Mark Kelly (twin control), 2015-2016
- JAXA CFE: 6 astronauts, >120 days ISS, cell-free RNA epigenome

## Benchmark Statistics
- 21 ML tasks: 19 main + 2 supplementary (E2, E3)
- 9 categories: Clinical, cfRNA, Proteomics, Metabolomics, Spatial, Microbiome, Multi-modal, Cross-tissue, Cross-mission
- Tiers: Calibration=1, Standard=5, Advanced=9, Frontier=6

## Baseline Results (Best per Task)
| Task | Tier | Best Model | Score |
|------|------|-----------|-------|
| A1 | Standard | LogReg | 0.546 |
| A2 | Standard | LogReg | 0.493 |
| B1 | Advanced | LightGBM | 0.922 |
| B2 | Advanced | LogReg | 0.154 |
| C1 | Standard | MLP | 0.517 |
| C2 | Frontier | LightGBM | 0.565 |
| D1 | Advanced | RF | 0.676 |
| E1 | Advanced | LogReg | 0.017 |
| E4 | Advanced | LogReg | 0.023 |
| F1 | Standard | LightGBM | 0.200 |
| F2 | Frontier | LightGBM | 0.280 |
| F3 | Calibration | RF | 0.841 |
| F4 | Standard | LogReg | 0.163 |
| F5 | Frontier | LightGBM | 0.304 |
| G1 | Advanced | LogReg | 0.517 |
| H1 | Advanced | LightGBM | 0.285 |
| I1 | Frontier | LightGBM | 0.006 |
| I2 | Advanced | LightGBM | 0.735 |
| I3 | Advanced | LogReg | 0.090 |

## Composite Scores (Normalized)
- RF: 0.258 (best overall)
- XGBoost: 0.250
- LightGBM: 0.238
- LogReg: 0.201
- MLP: 0.133

## Cross-Mission Facts
- 146/452 pathways conserved between I4 and Twins (32.3%)
- 814/15,540 genes show conserved DE (5.2%)
- 57 hemoglobin/erythropoiesis genes in the dataset
- HBB shows ~40% post-flight expression increase

## Key Limitations
- N=4 crew (I4), N=1 treatment (Twins) — extremely small sample sizes
- 3-day mission may not capture chronic adaptation effects
- LOCO evaluation stringent but low-N means high variance
- Cross-mission comparisons confounded by different platforms, crews, and durations

---

**Question (expert):** If you were designing a follow-up clinical monitoring study for a 6-crew, 30-day mission with weekly sampling, how would you modify the A1/A2 task design to improve statistical power while maintaining LOCO evaluation?

**Your Answer:**